We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+21.1%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
-$150M
(-5%)
Cap. Flow
-$428M
Cap. Flow
% of AUM
-14.96%
Top 10 Holdings %
Top 10 Hldgs %
28.09%
Holding
113
New
30
Increased
18
Reduced
43
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$83.4M |
| 2 |
AbbVie
ABBV
|
+$76M |
| 3 |
Eli Lilly
LLY
|
+$55.8M |
| 4 |
Pfizer
PFE
|
+$43.5M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$40.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$72.7M |
| 2 |
Surgery Partners
SGRY
|
+$68.7M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$65.2M |
| 4 |
Merck
MRK
|
+$63.8M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$56.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Technology | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Denali Therapeutics
DNLI
$3.78B
| $8.34M | 0.29% |
+282,752
| New | +$7.95M |
|
77
Collegium Pharmaceutical
COLL
$1.16B
| $7.61M | 0.27% |
354,100
-31,400
| -8% | -$713K |
|
78
Alphatec Holdings
ATEC
$1.35B
| $7.07M | 0.25% |
+393,000
| New | +$6.12M |
|
79
AN2 Therapeutics
ANTX
$179M
| $5.59M | 0.2% |
657,200
-66,000
| -9% | -$475K |
|
|
GRTS
80
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $5.39M | 0.19% |
+2,765,500
| New | +$6.48M |
|
81
Compass Therapeutics
CMPX
$384M
| $5.15M | 0.18% |
1,620,200
-204,800
| -11% | -$643K |
|
82
SCYNEXIS
SCYX
$36.3M
| $5.13M | 0.18% |
+217,342
| New | +$5.08M |
|
|
SYRS
83
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $4.61M | 0.16% |
1,464,034
+559,404
| +62% | +$1.8M |
|
84
Altimmune
ALT
$568M
| $4.14M | 0.14% |
1,174,100
-141,100
| -11% | -$633K |
|
85
Century Therapeutics
IPSC
$382M
| $3.51M | 0.12% |
1,110,900
-157,200
| -12% | -$507K |
|
86
Hyperfine
HYPR
$94.9M
| $2.55M | 0.09% |
1,188,178
-315,576
| -21% | -$514K |
|
87
Simulations Plus
SLP
$371M
| $1.99M | 0.07% |
+45,900
| New | +$2.01M |
|
|
CMAX
88
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $1.98M | 0.07% |
21,200
-3,978
| -16% | -$351K |
|
89
Bausch Health
BHC
$1.71B
| $1.72M | 0.06% |
+215,100
| New | +$1.59M |
|
90
Structure Therapeutics
GPCR
$3.49B
| $1.57M | 0.05% |
+37,800
| New | +$1.06M |
|
|
EXAI
91
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $755K | 0.03% |
+127,600
| New | +$782K |
|
92
Arteris
AIP
$1.37B
| $515K | 0.02% |
+75,500
| New | +$408K |
|
|
NUVB.WS
93
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
| $15K | ﹤0.01% |
90,560
-9,439
| -9% | -$1.47K |
|
94
Abbott
ABT
$184B
| – | – |
-354,000
| Closed | -$35.8M |
|
95
Arcutis Biotherapeutics
ARQT
$3.51B
| – | – |
-1,628,500
| Closed | -$17.9M |
|
96
Avantor
AVTR
$8.02B
| – | – |
-1,125,000
| Closed | -$23.8M |
|
97
BridgeBio Pharma
BBIO
$16.5B
| – | – |
-1,000,000
| Closed | -$16.6M |
|
98
BioAtla
BCAB
$5.66M
| – | – |
-12,050
| Closed | -$1.61M |
|
99
BioMarin Pharmaceuticals
BMRN
$11.7B
| – | – |
-300,575
| Closed | -$29.2M |
|
100
Cytokinetics
CYTK
$11B
| – | – |
-252,000
| Closed | -$8.87M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q2 2023 Portfolio in Review
As of Q2 2023, Avidity Partners Management held 113 positions worth $2.86B, down 5% from $3.01B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Avidity Partners Management withdrew a net $428M in Q2 2023, closing 20 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $63.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology.
Against the trend, Avidity Partners Management opened a new position in GE HealthCare worth $84.9M.
- Avidity Partners Management's largest Q2 2023 buy was GE HealthCare: 1,045,400 shares worth $84.9M.
- Avidity Partners Management added most to Cencora in Q2 2023, an estimated $30M increase.
- Avidity Partners Management's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $72.7M.
- Avidity Partners Management fully exited Merck in Q2 2023, selling an estimated $63.8M.
- Avidity Partners Management's ten largest holdings make up 28% of its $2.86B portfolio in Q2 2023.
- Avidity Partners Management opened 30 new positions and closed 20 in Q2 2023.
- Avidity Partners Management's portfolio value fell 5% quarter-over-quarter to $2.86B.
Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.